

1 α -HYDROXY PREVITAMIN D₃ AND ITS SELECTIVE
FORMATION FROM 1-KETO PREVITAMIN D₃

L.J. Vanmaele^a, P.J. De Clercq^a and M. Vandewalle^a *
S.J. Halkes^b * and W.R.M. Overbeek^b

^a Department of Organic Chemistry, State University of Ghent,
Laboratory for Organic Synthesis, Krijgslaan, 281 (S.4), B-9000 GENT (Belgium)

^b Duphar BV, P.O. Box, 2, 1380 AA WEESP (Holland)

(Received in UK 15 December 1983)

Summary - An efficient method for the preparation of crystalline 1 α -hydroxy previtamin D₃ is described. Also the stereoselective reduction of 1-keto previtamin 9 is discussed; it was observed that with aluminum hydride 7 is the most abundant product. This stands in contrast with previously reported LiAlH₄ and NaBH₄ mediated reductions.

The recognition¹ of the importance of 1 α -hydroxylated vitamin D₃ metabolites and analogs for mediating intestinal calcium absorption and bone calcium mobilization has stimulated the study of various approaches to their synthesis². However little attention so far has been devoted to practical syntheses of 1 α -hydroxylated previtamin D₃ (7), the fundamentally important minor isomer in the natural equilibrium vitamin D * previtamin D (20 % previtamin at 36°C). Among the existing methods leading to 1 α -hydroxy vitamin D₃, only the classical photochemical-thermal isomerization of 1 α -hydroxy provitamin D₃ provides a direct access to 1 α -hydroxy previtamin D₃ (7)^{3,4,5}.

One important reason for having good access to 1 α -hydroxy previtamin D₃ (7) is related to the observation of Mazur et al.⁴ indicating that of the two isomers 6 and 7 the latter is the better substrate for allylic oxidation^{4,6} to 1-keto previtamin D₃ (9). The reduction of 9 has been reported to yield predominantly (vide infra) 1 β -hydroxy vitamin D₃ (after thermal isomerization), which is a serious drawback with regard to eventual preparation of radiolabelled 1 α -hydroxy vitamin D₃.

In this context we wish to report on a modification of our previously described synthesis⁷ of 6 (1 + 3 + 4 + 5) which leads conve-

veniently to crystalline 1 α -hydroxy previtamin D₃ (7) and on the stereoselective reduction of 9 to 7 (and hence to 6).

Of crucial importance in our approach is the possibility of adequate protection, as a Diels-Alder adduct, of the 6,8 diene in previtamin D₃ (1) (obtained either from vitamin D₃ by equilibration or from provitamin D₃ by low temperature irradiation). This allows selective carbonyl introduction at C-1 affording the triazoline adduct 4, followed by stereoselective reduction to 5. The subsequent one pot (15 N KOH-MeOH, reflux, 70 hr, Ar) generation of the vitamin triene system (cf. 6) almost necessarily has to involve four discrete transformations: (1) saponification to the cyclic hydrazine 10; (2) oxidation to the elusive unsaturated azo derivative⁸; (3) facile stereospecific cycloreversion to the original previtamin skeleton 7; (4) thermal isomerization to 6 under the conditions used. In view of this scheme, however, the direct obtention of 6 merely implies that either the oxidation step (2) occurs in spite of the "inert" atmosphere or that another pathway is in fact involved^{8,9}. If the above cited sequence is operative it is obvious that when the reaction at higher temperature can be stopped at the stage of 10, subsequent low temperature oxidation would lead exclusively to 1 α -hydroxy

Table : Observed stereoselectivity upon reduction of 9

Reagent	<u>7</u> (1 α -OH)	<u>8</u> (1 β -OH)	Yield %	Ref.
NaBH ₄ , CH ₃ OH 0°C	0	1	70	4
LiAlH ₄ , ether, 0°C	1	2.8	60	4
LiAlH ₄ ^x , ether, -20°C	1	4	100	6
AlH ₃ , THF, -60°C	4	1	91	

^x inverse addition

Thus, when aluminum hydride is the reducing agent, faster interaction between the 3-hydroxyl group and the aluminum atom assures internal hydride introduction at C-1.

Because of the obvious advantage of introducing the label in the last step in the synthesis of a radioactive compound our result offers the possibility for a suitable preparation of 1 β -tritium labelled 1 α -hydroxylated vitamin D₃.

EXPERIMENTAL SECTION

The m.p.s. are uncorrected. IR spectra were recorded on a Beckman IR 4230 spectrophotometer, UV spectra on a Unicam SP 1750 Ultraviolet Spectrophotometer and mass spectra on a AEI MS-50 spectrometer. The ¹H NMR spectra were recorded at 360 MHz (WH-Brucker) in CDCl₃ unless otherwise stated with TMS as internal standard. Chemical shifts (δ) are expressed in ppm. Rf values are quoted for Merck silica gel 60 GF254 TLC plates of thickness 0.25 mm.

Reaction products were isolated by the addition of water and extraction with diethyl ether. The combined extracts were washed with brine and dried over MgSO₄. The solvent was removed from the filtered solution on a rotary evaporator. Column chromatographic separations were performed on silica gel, on a Prep LC/System 500 (Waters) apparatus or on a Model 6000 A Solvent Delivery System HPLC (Waters).

Formation of the dibenzamide 12

A soln of KOH in degassed H₂O (21 mL; 112 g in 84 mL H₂O) was added dropwise to a soln of 3 (500 mg; 0.89 mmol) in degassed CH₃OH (21 mL) at 110°C. Oxygen-free argon was passed through the soln at 110°C for 70 h. After cooling, the soln was extracted under argon with CH₂Cl₂ (5 x 50 mL). After work-up under argon and evaporation, the residue was dissolved in dry Et₂O (4 mL) and pyridine (0.07 mL). Benzoyl chloride (0.1 mL) was added dropwise to the soln at 0°C. After stirring for 2 h an ice-water mixture was added. Extraction with Et₂O, work-up and column chro-

matography (HPLC; hexane/acetone; 85:15) afforded 12 (202 mg; 36 %). Vitamin D₃ (2), previtamin D₃ (1) and their benzoates were also formed. Rf (benzene/acetone; 9:1) = 0.25. 12: UV (CH₃OH): λ_{\max} = 213 nm. IR (KBr): 3420, 3050, 2940, 2920, 2860, 1680, 1635, 1600, 1580, 1490, 1460, 1440, 1370, 1330, 1280, 910 cm⁻¹. ¹H NMR: 0.880 (d, J = 6.5 Hz, 3), 0.882 (d, J = 6.5 Hz, 3), 0.90 (s, 3), 0.94 (d, J = 5 Hz, 3), 1.26 (s, 3), 3.72 (m, 1), 4.75 (m, 1), 5.19 (s, 1), 5.61 (m, 1), 7.17 (m, 2), 7.30-7.44 (m, 6), 7.64 (m, 2). MS: m/z 622 (M⁺, 9), 394 (63), 106 (44), 105 (100), 77 (100), 43 (58).

1(s)-Hydroxy previtamin D₃ (7)

From 1-keto previtamin D₃ 9:

A soln of AlCl₃ (128 mg; 0.942 mmol) in dry THF (3.2 mL) was added to a suspension of LiAlH₄ (108 mg; 2.826 mmol) in dry THF (10 mL) at ambient temp. The suspension was placed in an ultrasonic bath for ten min.

A soln of AlH₃ (0.942 mmol; 3.3 mL of the prep. soln) was added dropwise to a soln of 1-keto previtamin D₃ (9) (75 mg; 0.1884 mmol) in dry THF (0.8 mL) at -70°C. After stirring for an additional 30 min at -60°C 5 % HCl soln (2 mL) and THF (2 mL) were added. Extraction with diethylether (3 x 30 mL), work-up and column chromatography (HPLC; hexane/acetone; 8:2) afforded 7 (55 mg) and 1(R)-hydroxy previtamin D₃ (8) (14 mg). The total yield was 91.5 % and the ratio 1(S)/1(R) \sim 4/1.

7: m.p. = 120-122°C (Et₂O); Rf (benzene/acetone; 7:3) = 0.29. UV (CH₃OH): λ_{\min} = 234 nm, λ_{\max} = 260 nm. IR (KBr): 3500, 3040, 3000, 2980, 2960, 1650-1600, 1470, 1390 cm⁻¹. ¹H NMR: 0.70 (s, 3H), 0.866 (d, J = 6.8 Hz, 3), 0.871 (d, J = 6.8 Hz, 3), 0.94 (d, J = 6.4 Hz, 3), 1.77 (s, 3), 4.05 (m, FWHM = 24 Hz, 1), 4.20 (m, FWHM = 9 Hz, 1), 5.50 (m, 1), 5.79 (d, J = 12 Hz, 1), 5.91 (d, J = 12 Hz, 1).

8: Rf (benzene/acetone; 7:3) = 0.42. UV (CH₃OH) λ_{\min} = 228 nm, λ_{\max} = 256 nm. ¹H NMR: 0.71 (s, 3), 0.867 (d, J = 6.5 Hz, 3), 0.872 (d, J = 6.5 Hz, 3), 0.94 (d, J = 6.5 Hz, 3), 1.81 (s, 3), 4.02 (m, FWHM = 10 Hz, 1), 4.24 (m, FWHM = 11 Hz, 1), 5.55 (m, 1), 5.79 (d, J = 12 Hz, 1), 5.95 (d, J = 12 Hz, 1).

From adduct 5:

A soln of KOH in degassed H₂O (30 mL; 112 g in 84 mL H₂O) was added to a soln of 5 (600 mg; 1.0435 mmol) in degassed CH₃OH (30 mL) at 110°C. Oxygen-free argon was passed through the soln at 110°C and the reaction was monitored by TLC. After completion CH₃OH was removed upon distillation under argon. Et₂O (30 mL) and CH₂Cl₂ (20 mL) were added at 0°C and the water layer was extracted with Et₂O-CH₂Cl₂ (3:2; 5 x 40 mL). The combined organic layers were washed with brine until neutral. At 0°C air was passed through the soln for 24 h. Work-up and column chromatography (HPLC; hexane/acetone; 8:2) afforded 7 (230 mg; 55 %).

Acknowledgments: The "Nationaal Fonds voor Wetenschappelijk Onderzoek" (NFWO) and the "Ministerie voor Wetenschapsbeleid" are gratefully acknowledged for financial support to the laboratory. L.J.V., Research Fellow of the NFWO, and P.J.D.C., Research Associate of the NFWO, thank the Fund for their positions.

References

- H.F. DeLuca, H.K. Schnoes, Annu. Rev. Biochem., **45**, 631-666 (1976); P.E. Georghiou, Chem. Soc. Rev., **6**, 83 (1977).

2. B. Lythgoe, *Chem. Soc. Rev.*, 9, 449 (1980).
H. Jones, G.H. Rasmusson, *Fortschr. Chem. Org. Naturst.*, 39, 121 (1980).
3. D.H.R. Barton, R.H. Hesse, M.M. Pechet, E. Rizzardo, (a) *J. Am. Chem. Soc.*, 95, 2748 (1973); (b) *J.C.S. Chem. Comm.*, 203 (1974).
4. M. Sheves, N. Friedman, Y. Mazur, *J. Org. Chem.*, 42, 3597 (1977).
5. W.G. Dauben, R.B. Phillips and P. Jefferies, *Proc. Natl. Acad. Sci. USA*, 79, 5115 (1982).
6. H.E. Paaren, H.K. Schnoes, H.F. DeLuca, *J.C.S. Chem. Comm.*, 890 (1977).
7. L.J. Vanmaele, P.J. De Clercq, M.E. Vandewalle, *Tetrahedron Lett.*, 23, 995 (1982).
8. This step is assumed in view of the much higher reactivity for cycloreversion of unsaturated azo compounds compared to the corresponding unsaturated hydrazo compounds; see : B.T. Gillis and P.E. Beck, *J. Org. Chem.*, 28, 3177 (1963); J.A. Berson, S.S. Olin, E.W. Petrillo, Jr., P. Bickart, *Tetrahedron*, 30, 1639 (1974) and references cited therein.
9. W. Reischl, E. Zbiral, *Liebigs Ann. Chem.*, 745 (1978); D.J. Aberhart, A. Chi-Tung Hsu, *J. Org. Chem.*, 41, 2098 (1976).